ArticleMedicine2019
Essential oil extracted from erythrina corallodendron L. leaves inhibits the proliferation, migration, and invasion of breast cancer cells.
Article in Medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 21 citations in OpenAlex.
- Targeted phytotherapy: essential oils, multi-target cancer action & nanodelivery.Frontiers in oncology · 2026Review
- In Silico and In Vitro Evaluation of δ-cadinene fromCancers · 2025Article
- Plant-based secondary metabolites as natural remedies: a comprehensive review on terpenes and their therapeutic applications.Frontiers in pharmacology · 2025Review
- Anticancer Effect ofMolecules (Basel, Switzerland) · 2024Article
- Anticancer effect of terpenes: focus on malignant melanoma.Pharmacological reports : PR · 2023Review
- The Leaf Essential Oil ofPlants (Basel, Switzerland) · 2023Article
- Pharmacology activity, toxicity, and clinical trials of Erythrina genus plants (Fabaceae): an evidence-based review.Frontiers in pharmacology · 2023Review
- GC, GC/MS Analysis, and Biological Effects of Essential Oils fromPlants (Basel, Switzerland) · 2022Article
- Anticancer properties of medicinal plants and their bioactive compounds against breast cancer: a review on recent investigations.Environmental science and pollution research international · 2022Review
- Exploration of Chemopreventive Potential of Linalool in Targeting Lung Cancer Biomarkers.Endocrine, metabolic & immune disorders drug targets · 2022Article
- Biological evaluation of linalool on the function of blood vessels.Molecular medicine reports · 2021Article
- Chemical composition and pharmacological bio-efficacy ofSaudi journal of biological sciences · 2021Article
- Linalool inhibits the angiogenic activity of endothelial cells by downregulating intracellular ATP levels and activating TRPM8.Angiogenesis · 2021Article
- Ameliorative Effect of Linalool in Cisplatin-Induced Nephrotoxicity: The Role of HMGB1/TLR4/NF-κB and Nrf2/HO1 Pathways.Biomolecules · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Erythrina corallodendron L., a kind of landscape tree, has long been used as a traditional medicine. In this study, the composition of essential oil extracted from the leaves was analysed by GC-MS (gas chromatograph-mass spectrometer), with linalool identified as the main compound. Its cytotoxicity against MDA-MB-231, MCF-7 and HMLE cells was examined by MTT and cloning assays. Transwell and wound-healing assays were used to examine the inhibition of migration and invasion. Western blot, qRT-PCR and immunofluorescence staining were used to measure the mRNA and protein expression of factors related to EMT (snail, slug, E-cadherin, N-cadherin and vimentin). The essential oil of Erythrina corallodendron leaves was found to inhibit the proliferation, migration and invasion of breast cancer cells in a dose-dependent manner. The findings of this study suggest that the essential oil of E. corallodendron leaves may merit further investigation as a potential clinical or adjuvant drug for treating breast cancer migration and invasion.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.